Summary: I find the current share price to be too conservative for this quality company and expect that the return in the coming year will come from multiples expansion (from PE 16.6 to 18), dividend of 3.5% (EUR 0.75 / 21 EUR per share) and future earnings growth (5 year historic earnings growth of CAGR 33%).
About the company: Valmet Oyj is a Finnish company with an industrial history over 200 years. As a standalone listed company, the history stretches only back to 2013, when it was spun off from Metso Corporation. Valmet is the leading global developer and supplier of technologies, automation and services for the pulp, paper and energy industries.
The company has four segments:
- Pulp and Energy
At Valmet, Services and Automation are considered to be “stable” businesses, as they represent rather stable and slightly growing markets that are driven by the size of the installed base and mill operating rates. Currently, the increasing consumption of board, tissue and pulp in particular, as well as demand for bioenergy, are boosting production growth, which is creating new demand for Valmet’s services and automation (source: Valmet Investor Relations)
Pulp and Energy and Paper business, such as board, paper and tissue machines, pulp mills, and biomass power boilers are referred to as “capital” businesses. They are driven by new investments in machinery and mills, which makes these businesses more cyclical and volatile compared to the more stable services and automation businesses (source: Valmet Investor Relations)
Pulp & Paper industry: Paper and packaging experiencing several “megatrends”, which are important demand drivers for new packaging and consumer board products.
- Digitalisation (headwind for traditional paper and print industry)
- A rapidly growing global middle class,
- Eco awareness
- Population growth
- Booming e-commerce
Valmet scores 86 points in my investment checklist, which is above my treshold of 80 points.
- Lower pulp prices may reduce the willingness to invest in Valmet’s products
- Weaker economic outlook in the overall economy
- Climate change may cause increased damage to the forest from the bark beetle in Central Europe.
- Project-specific risk (project cost estimation, scheduling, quality and performance)
The current dividend yield is ~3.0 % and has increased since the IPO in 2013. The current payout ratio is 50.2% and the ratio has declined since the IPO, which is a result of increased earnings and growth. Net debt / EBITDA is 0,69 and the net debt is 7.7 % ( Net debt shows how much net interest-bearing liabilities in the company in relation to total assets ). The dividend safety is satisfactory, and I expect an increase for 2019 to EUR 0.75 per share (increase of 15%).
The stock is currently trading at P/E 16.6 (P/E 2020E is 13.7 Source: Bloomberg consensus) which is fairly conservative for this company on a historical basis and compared to peers (e.g. ABB, Honeywell and other industrials). I expect a return on my investment of ~45 % and a share price of EUR 30. This is based on the current conservative pricing, which gives room for multiples expansion (based on historic multiples and peers), combined with expected earnings growth and a dividend yield of 3%.
Summary: Entered a «kangaroo market», and a possible market top on 8 June Still a high cash position, but exploited some good opportunities Takeover bid for one of my holdings Initiated a position in Evolution Gaming as a hedge in case the bid on NetEnt fails Added to my positions in Bakkafrost, Mowi and Essity… Continue reading Monthly report 6-2020
Summary: Another great month in the stock market, and I’m becoming more and more cautious for every market uptick The refined strategy; «Nordic Compounders» is on track and operational Portfolio is outperforming every benchmark, even with a large cash position, and close to a new all time high Cash position of 25.6% Current portfolio is… Continue reading Monthly report 5-2020
Today I sold my position in Boule Diagnostics at 65.8 SEK per share. The reason why is that my investment thesis has played out, and because I only rank the company as a «Class 4»-company. This is what I wrote on 1 October: «The share price has plummeted due to the american FDA putting their… Continue reading No longer bull on Boule Diagnostics